Clinical Trial Search

Primary: Percentage of Participants With Febrile Neutropenia (FN) — 8; 8; 15; 9 percentage of participants

Primary: DSN — 0.15; 0.36; 0.43; 0.29 days

Primary: Percentage of Participants With Febrile Neutropenia — 3.3; 1.9; 0.4; 0.5 percentage of participants

Primary: Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia — 73.4; 88.3; 41.1; 25.0 percentage of investigators

Primary: Percentage of Participants With Any Significant Comorbidities — 42.7 percentage of participants

Primary: Chemotherapy Toxicity (%FN Risk) — 154; 650; 640; 3 participants

Primary: Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin. — 16 participants

Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants

Primary: Duration of Severe Neutropenia (DSN) — 0.246; 0.770 Days

Primary: Percentage of Participants With CSF Prescribed as Primary Prophylaxis — 8.3; 5.5; 7.2; 5.3 percentage of participants — p=0.21

Primary: Incidence of Infection — 6 infections

Primary: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy — 0.75; 0.83; 0.75; 0.79 days — p=0.05

Primary: Duration of Severe Neutropenia in Cycle 1 — 0.9; 1.6; 1.1; 0.9 days

Primary: Compare Differences in HRQOL Scores Between Outpatient Versus Inpatient Management — 70.1; 68.7 score on a scale

Primary: Double-Blind Phase: Duration of Severe Neutropenia in Cycle 1 — 1.0; 1.1 days

Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants

Primary: Overall Complete Response Rate — 10; 10 percentage of participants

Primary: Unplanned Chemotherapy Treatment Delay — 16 Participants

Primary: Grade 3 or 4 Neutropenia — 16; 51 Participants — p=<0.0001

Primary: Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting — 13 participants

Primary: Number of Participants With Proven/Probable/Possible Invasive Fungal Infection — 1; 0; 2; 62 Participants

Primary: Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group — 300; 250 ug/mL*hr

Primary: Duration of Neutropenia CTCAE Grade 4 — 0.905; 0.791; 1.725 days

Primary: Comparison of Cumulative Incidence of Anti-pegfilgrastim Antibodies (Binding and Neutralizing) to Pegfilgrastim Between Treatment Groups at the End of Cycle 4 (Day 84)…

Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants

Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…

Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 0.31; 0.39 Days — p=< 0.0001

Primary: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 — 0.2; 0.2 days

Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73

Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants